--- title: "U.S. RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals" type: "News" locale: "en" url: "https://longbridge.com/en/news/299860089.md" datetime: "2026-09-23T07:36:53.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/299860089.md) - [en](https://longbridge.com/en/news/299860089.md) - [zh-HK](https://longbridge.com/zh-HK/news/299860089.md) generator: "portal-rs" --- # U.S. RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals Sept 23 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Allstate, Autozone and Vertex Pharmaceuticals on Wednesday. ### HIGHLIGHTS - Allstate Corp (ALL.N) : TD Cowen raises target price to $260 from $231 - Autozone, Inc. (AZO.N) : D.A. Davidson cuts target price to $3,500 from $3,750 - Martin Marietta Materials, Inc. (MLM.N) : Jefferies cuts target price to $670 from $720 - Vertex Pharmaceuticals Inc (VRTX.O) : Jefferies raises target price to $640 from $633 - Vulcan Materials Co (VMC.N) : Jefferies cuts target price to $320 from $345 Following is a summary of research actions on U.S. companies reported by Reuters on Wednesday. Stock entries are in alphabetical order. - Acadia Healthcare Company, Inc. (ACHC.O) : Leerink Partners raises PT to $33 from $30 - Allstate Corp (ALL.N) : TD Cowen raises target price to $260 from $231 - Amgen Inc (AMGN.O) : Jefferies raises target price to $410 from $367 - Anaptysbio, Inc. (ANAB.O) : Leerink Partners cuts target price to $81 from $90 - Anixa Biosciences Inc (ANIX.O) : H.C. Wainwright cuts target price to $6 from $7 - Autozone, Inc. (AZO.N) : D.A. Davidson cuts target price to $3,500 from $3,750 - Autozone, Inc. (AZO.N) : Exane BNP Paribas cuts target price to $3561 from $3979 - Autozone, Inc. (AZO.N) : Roth MKM cuts target price to $3850 from $4023 - Autozone, Inc. (AZO.N) : TD Cowen cuts target price to $3,400 from $3,500 - Bank7 Corp (BSVN.O) : KBW raises target price to $62 from $56 - Carnival Corp (CCL.N) : Jefferies cuts target price to $33 from $35 - Celldex Therapeutics Inc. (CLDX.O) : Leerink Partners raises target price to $88 from $70 - Compass Therapeutics Inc. (CMPX.O) : Guggenheim cuts target price to $4 from $8 - Compass Therapeutics Inc. (CMPX.O) : Jefferies cuts target price to $3 from $8 - Compass Therapeutics Inc. (CMPX.O) : Wedbush cuts to neutral from outperform - Compass Therapeutics Inc. (CMPX.O) : Wedbush cuts target price to $1 from $5 - Cummins (CMI.N) : JP Morgan cuts target price to $600 from $690 - Dauch Corp (DCH.N) : Jefferies cuts to hold from buy; cuts target price to $7.10 from $8.25 - Graphic Packaging Holding Company (GPK.N) : JP Morgan raises to overweight from neutral - Graphic Packaging Holding Company (GPK.N) : JP Morgan cuts target price to $11.5 from $12.5 - Guardian Pharmacy Services Inc (GRDN.N) : Keybanc initiates with overweight rating; PT $52 - KB Home (KBH.N) : Barclays cuts target price to $49 from $57 - KB Home (KBH.N) : RBC cuts target price to $50 from $53 - KB Home (KBH.N) : Truist Securities cuts target price to $50 from $55 - Martin Marietta Materials, Inc. (MLM.N) : Jefferies cuts target price to $670 from $720 - Marvell Technology (MRVL.O) : Seaport Research Partners initiates with buy rating; PT $270 - Merck & Co Inc (MRK.N) : TD Cowen raises target price to $155 from $137 - Onsemi (ON.O) : Seaport Research Partners initiates coverage with buy rating; PT $100 - Semtech Corp (SMTC.O) : Seaport Research Partners initiates with buy rating; target $200 - SiTime Corporation (SITM.O) : Seaport Research Partners initiates coverage with neutral rating - Thor Industries, Inc. (THO.N) : Jefferies cuts target price to $82 from $90 - UiPath Inc (PATH.N) : RBC cuts target price to $15 from $17 - Vertex Pharmaceuticals Inc (VRTX.O) : Jefferies raises target price to $640 from $633 - Viking Therapeutics, Inc. (VKTX.O) : Oppenheimer raises target price to $120 from $100 - Viking Therapeutics, Inc. (VKTX.O) : Truist Securities raises target price to $87 from $83 - Vulcan Materials Co (VMC.N) : Jefferies cuts target price to $320 from $345 ### Related Stocks - [AZO.US](https://longbridge.com/en/quote/AZO.US.md) - [VMC.US](https://longbridge.com/en/quote/VMC.US.md) - [ALL.US](https://longbridge.com/en/quote/ALL.US.md) - [AMGN.US](https://longbridge.com/en/quote/AMGN.US.md) - [MLM.US](https://longbridge.com/en/quote/MLM.US.md) - [VRTX.US](https://longbridge.com/en/quote/VRTX.US.md) - [ACHC.US](https://longbridge.com/en/quote/ACHC.US.md) - [ANAB.US](https://longbridge.com/en/quote/ANAB.US.md) - [ANIX.US](https://longbridge.com/en/quote/ANIX.US.md) - [BSVN.US](https://longbridge.com/en/quote/BSVN.US.md) - [CCL.US](https://longbridge.com/en/quote/CCL.US.md) - [CLDX.US](https://longbridge.com/en/quote/CLDX.US.md) - [CMPX.US](https://longbridge.com/en/quote/CMPX.US.md) - [CMI.US](https://longbridge.com/en/quote/CMI.US.md) - [DCH.US](https://longbridge.com/en/quote/DCH.US.md) - [GPK.US](https://longbridge.com/en/quote/GPK.US.md) - [GRDN.US](https://longbridge.com/en/quote/GRDN.US.md) - [KBH.US](https://longbridge.com/en/quote/KBH.US.md) - [MRVL.US](https://longbridge.com/en/quote/MRVL.US.md) - [MRK.US](https://longbridge.com/en/quote/MRK.US.md) - [ON.US](https://longbridge.com/en/quote/ON.US.md) - [SMTC.US](https://longbridge.com/en/quote/SMTC.US.md) - [SITM.US](https://longbridge.com/en/quote/SITM.US.md) - [THO.US](https://longbridge.com/en/quote/THO.US.md) - [PATH.US](https://longbridge.com/en/quote/PATH.US.md) - [VKTX.US](https://longbridge.com/en/quote/VKTX.US.md) - [ALL-B.US](https://longbridge.com/en/quote/ALL-B.US.md) - [ALL-H.US](https://longbridge.com/en/quote/ALL-H.US.md) - [ALL-I.US](https://longbridge.com/en/quote/ALL-I.US.md) - [ALL-J.US](https://longbridge.com/en/quote/ALL-J.US.md) - [CCL.UK](https://longbridge.com/en/quote/CCL.UK.md) - [CUK.US](https://longbridge.com/en/quote/CUK.US.md) ## Related News & Research - [What Allstate (ALL)'s Catastrophe Losses Mean For Shareholders](https://longbridge.com/en/news/300205658.md) - [How Phase 3 Sjögren’s Results At Amgen (AMGN) Has Changed Its Investment Story](https://longbridge.com/en/news/300175029.md) - [2 Healthcare Stocks That Just Delivered Great News for Investors](https://longbridge.com/en/news/300206760.md) - [TD Cowen maintains Buy rating on AutoZone, $3400 price target](https://longbridge.com/en/news/299913536.md) - [Analyst Maintains Buy on AutoZone with $3,500 Unchanged Price Target Despite Softer FQ4 Results](https://longbridge.com/en/news/299870035.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**